Anemia and Its Management in Chronic Kidney Disease

To determine if a patient needs iron, clinicians look at two key laboratory values:

1. Ferritin: A measure of stored iron. The target for CKD patients is to maintain ferritin $< 500 \text{ ng/mL}$.
2. Transferrin Saturation (TSAT): A measure of how much iron is available for transport. The target is to maintain TSAT $> 30\%$.

Oral vs. IV Iron

Depending on the patient's needs and tolerance, iron can be administered via two routes:

• Oral Iron: Options include ferrous sulfate, ferrous fumarate, and ferric citrate. Oral iron is more cost-effective but may be less effective in advanced CKD or dialysis patients. For maximum absorption, oral iron should be taken on an empty stomach. Common side effects include constipation, nausea, and dark stools.
• Intravenous (IV) Iron: Indicated if oral iron is ineffective or for patients on dialysis. Common options include Iron Sucrose (Venofer) and Ferumoxytol (Feraheme).
  • Warning: Iron dextran (INFeD) carries a Black Box Warning for anaphylaxis and requires a $25 \text{ mg}$ test dose administered 30–60 minutes before the full dose.

Step 2: Erythropoiesis-Stimulating Agents (ESA)

If hemoglobin levels remain low (specifically $< 10 \text{ g/dL}$) after iron stores have been corrected, Erythropoiesis-Stimulating Agents (ESAs) are indicated. These are synthetic formulations of EPO that mimic the natural hormone to stimulate red blood cell production.

Common ESAs include:

• Epoetin alfa (Epogen, Procrit)
• Darbepoetin alfa (Aranesp) — notable for having an increased half-life, allowing for less frequent dosing.
• Methoxy Polyethylene Glycol-Epoetin Beta (Micera) — provides the longest half-life, allowing for monthly dosing.

⚠️ Black Box Warning: ESAs carry a significant risk of serious cardiovascular events (MI, CVA, VTE) and increased mortality if the target hemoglobin is pushed too high (specifically if $\text{Hgb} > 11 \text{ g/dL}$).

The most common side effect of ESA therapy is hypertension. Clinicians should exercise caution if a patient's baseline blood pressure is $> 180/100 \text{ mmHg}$.

Nutritional Considerations in CKD

While dietary iron can be part of a holistic approach, it is rarely sufficient on its own to manage CKD anemia. Furthermore, managing CKD requires careful control of other nutrients to slow disease progression.

Protein Intake Management: Excessive protein intake can increase the workload on remaining nephrons. Therefore, protein should be limited based on the patient's status:

• General CKD adults: $\le 1.3 \text{ g/kg/day}$.
• Patients with Diabetes or GFR $< 30$: $< 0.8 \text{ g/kg/day}$.
• Dialysis patients: $1.2 \text{ g/kg/day}$ (higher protein is needed to compensate for losses during dialysis).

Additionally, sodium intake should be limited to $< 2 \text{ g/day}$ to help manage blood pressure and fluid retention.

Summary Table: Anemia Management Workflow